Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets

v3.23.3
Intangible Assets
 9 Months Ended
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Intangible Assets
Intangible assets as of September 30, 2023 and December 31, 2022 consist of the following (in $000’s):
September 30,
2023		 December 31,
2022
Patent and domains $ 4  $ 4 
Soin intangibles * $ 19,293  $ 19,293 
Computer software —  3,563 
Intangible assets from discontinued operations —  735 
Intangible assets 19,297  23,595 
Less accumulated amortization (1,089) (3,563)
Total intangible assets $ 18,208  $ 20,032 
*The Soin intangibles acquired by the Company consist of the following:
1.Three pending patents related to the methods of using low-dose Naltrexone to treat chronic pain;
2.Final formula for Naltrexone; and
3.Orphan drug designation as approved by the FDA.
Intangible amortization expense from continuing operations was $363,000 and $0 for the 13 weeks ended September 30, 2023 and October 1, 2022 and $1.1 million and $0 for the 39 weeks ended September 30, 2023 and October 1, 2022.